Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carmoterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 20/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 18/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carmoterol SCHEMBL594076 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL29355060 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL10494473 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL364838 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL10494299 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL10494565 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL11912044 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL5990417 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL465645 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL10494358 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090280068-A1 | POLYMORPH OF 8-HYDROXY-5-[(1R)-1-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMINO]ETHYL]-2(1H)-QUINOLINONE MONOHYDROCHLORIDE | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-11-12 | — | — | US | claimed |
| EP-1381346-A2 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL FOR DELIVERY TO THE LUNGS VIA NEBULIZATION | Dey L.P. (US) | 2004-01-21 | — | — | EP | disclosed |
| WO-2002083079-A2 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL FOR DELIVERY TO THE LUNGS VIA NEBULIZATION | DEY, L.P. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280068-A1 | POLYMORPH OF 8-HYDROXY-5-[(1R)-1-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMINO]ETHYL]-2(1H)-QUINOLINONE MONOHYDROCHLORIDE | UGT1A8, HTR1D, UGT1A1 | ADRB2 651/4885ADRB1 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.